276 related articles for article (PubMed ID: 18566298)
1. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
Lamon-Fava S; Diffenderfer MR; Barrett PH; Buchsbaum A; Nyaku M; Horvath KV; Asztalos BF; Otokozawa S; Ai M; Matthan NR; Lichtenstein AH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1672-8. PubMed ID: 18566298
[TBL] [Abstract][Full Text] [Related]
2. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
3. Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
Brinton EA; Triscari J; Brudi P; Chen E; Johnson-Levonas AO; Sisk CM; Ruck RA; MacLean AA; Maccubbin D; Mitchel YB
Lipids Health Dis; 2016 Jul; 15(1):116. PubMed ID: 27405296
[TBL] [Abstract][Full Text] [Related]
4. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status.
Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH
Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247
[TBL] [Abstract][Full Text] [Related]
5. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
6. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism.
Lamon-Fava S; Diffenderfer MR; Barrett PH; Buchsbaum A; Matthan NR; Lichtenstein AH; Dolnikowski GG; Horvath K; Asztalos BF; Zago V; Schaefer EJ
J Lipid Res; 2007 Aug; 48(8):1746-53. PubMed ID: 17526934
[TBL] [Abstract][Full Text] [Related]
7. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
9. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
Farnier M; Chen E; Johnson-Levonas AO; McCrary Sisk C; Mitchel YB
Vasc Health Risk Manag; 2014; 10():279-90. PubMed ID: 24855368
[TBL] [Abstract][Full Text] [Related]
10. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
[TBL] [Abstract][Full Text] [Related]
11. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
[TBL] [Abstract][Full Text] [Related]
12. Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Diabetes Obes Metab; 2016 Apr; 18(4):384-91. PubMed ID: 26679079
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.
Batista MC; Welty FK; Diffenderfer MR; Sarnak MJ; Schaefer EJ; Lamon-Fava S; Asztalos BF; Dolnikowski GG; Brousseau ME; Marsh JB
Metabolism; 2004 Oct; 53(10):1255-61. PubMed ID: 15375779
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner.
Le NA; Diffenderfer MR; Thongtang N; Ooi EM; Barrett PH; Horvath KV; Dolnikowski GG; Asztalos BF; Schaefer EJ; Brown WV
Lipids; 2015 May; 50(5):447-58. PubMed ID: 25809021
[TBL] [Abstract][Full Text] [Related]
15. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
Arad Y; Ramakrishnan R; Ginsberg HN
J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.
Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
[TBL] [Abstract][Full Text] [Related]
18. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
Savinova OV; Fillaus K; Harris WS; Shearer GC
Atherosclerosis; 2015 Jun; 240(2):520-5. PubMed ID: 25932792
[TBL] [Abstract][Full Text] [Related]
19. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
[TBL] [Abstract][Full Text] [Related]
20. Human apolipoprotein A-I kinetics within triglyceride-rich lipoproteins and high density lipoproteins.
Vélez-Carrasco W; Lichtenstein AH; Barrett PH; Sun Z; Dolnikowski GG; Welty FK; Schaefer EJ
J Lipid Res; 1999 Sep; 40(9):1695-700. PubMed ID: 10484617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
